BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Chengdu Zenitar Biomedical Technology readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Chengdu Zenitar Biomedical Techno
 logy's drugs run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05563844-3154@assetmemo.bio
DTSTAMP:20261121T010439Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Purinostat Mesylate: Phase 2 readout est. (NCT05563844)
DESCRIPTION:Purinostat Mesylate\, phase 2\, Diffuse Large B-Cell Lymphoma.\
 nStudy: Study of Purinostat Mesylate for Injection in the Treatment of Rel
 apsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)\nEstimated p
 rimary completion: 30 December 2026. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/purinostat-mesylate#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT05563844
URL:https://assetmemo.bio/drug/purinostat-mesylate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07193589-51@assetmemo.bio
DTSTAMP:20261121T010439Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:ZL-82: Phase 2 readout est. (NCT07193589)
DESCRIPTION:ZL-82\, phase 2\, Atopic Dermatitis.\nStudy: A Phase II Clinica
 l Study Evaluating of ZL-82 Tablets in Atopic Dermatitis\nEstimated primar
 y completion: 30 December 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/zl-82#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07193589
URL:https://assetmemo.bio/drug/zl-82#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07011056-3154@assetmemo.bio
DTSTAMP:20261121T010439Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Purinostat Mesylate: Phase 3 readout est. (NCT07011056)
DESCRIPTION:Purinostat Mesylate\, phase 3\, Diffuse Large B-Cell Lymphoma.\
 nStudy: A Phase III Clinical Study of Purinostat Mesylate for Injection in
  Patients With Diffuse Large B-cell Lymphoma\nEstimated primary completion
 : 30 June 2029. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/purin
 ostat-mesylate#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07011056
URL:https://assetmemo.bio/drug/purinostat-mesylate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
